Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

This trial is comparing a hormone-based treatment approach (dalpiciclib plus an aromatase inhibitor, given before surgery) against standard chemotherapy as pre-surgical treatment for postmenopausal women with early-stage breast cancer that is strongly estrogen receptor-positive and HER2-negative. The goal is to see if the less toxic hormone approach works just as well as chemotherapy. **You may be eligible if...** - You are a confirmed postmenopausal woman - You have been diagnosed with early invasive breast cancer (stage T1–T3, N1, M0) - Your tumor is strongly estrogen receptor-positive (ER+, ≥ 50% cells) and HER2-negative - You have not had any prior breast cancer treatment - Your heart function is normal (LVEF ≥ 50%) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have bilateral (both breast) or inflammatory breast cancer - Your cancer has already spread to distant organs (stage IV) - You are pregnant or breastfeeding - You have serious heart conditions (heart failure, recent heart attack, or significant arrhythmias) - You have active serious liver disease or severe HBV/HCV infection - You have a known severe allergy to any study drug component Talk to your doctor to see if this trial is right for you.